Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
155 hedge funds and large institutions have $1.02B invested in Adverum Biotechnologies in 2020 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 53 increasing their positions, 51 reducing their positions, and 29 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
4% more capital invested
Capital invested by funds: $980M → $1.02B (+$42.7M)
4% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 51
3% less funds holding
Funds holding: 160 → 155 (-5)
3.2% less ownership
Funds ownership: 100.02% → 96.82% (-3.2%)
17% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 29
34% less call options, than puts
Call options by funds: $7.76M | Put options by funds: $11.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$23.2M |
| 2 |
SFI
Sonic Fund II
Honolulu,
Hawaii
|
+$12.3M |
| 3 |
O
OrbiMed
New York
|
+$11.3M |
| 4 |
CC
Casdin Capital
New York
|
+$11.1M |
| 5 |
AG
Artal Group
Luxembourg
|
+$8.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
-$24.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$16.9M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$12M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$11.8M |
| 5 |
Two Sigma Investments
New York
|
-$4.77M |
ADVM Hedge Fund Activity: Q4 2020 in Review
155 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q4 2020, worth a combined $1.02B — up 4.4% from $980M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ADVM and 24 opened new positions — a net loss of 5 holders — while 51 trimmed existing stakes and 53 added.
The largest buyer was UBS Group, adding an estimated $23.2M. The largest seller was Versant Venture Management, cutting an estimated $24.7M.
- 155 institutional investors held Adverum Biotechnologies (ADVM) as of Q4 2020, down from 160 in Q3 2020.
- Funds reported $1.02B of Adverum Biotechnologies stock for Q4 2020, up 4.4% quarter-over-quarter.
- 24 funds opened new Adverum Biotechnologies positions in Q4 2020 and 29 closed out, a net change of -5 holders.
- The largest Adverum Biotechnologies buyer in Q4 2020 was UBS Group, an estimated $23.2M added.
- The largest Adverum Biotechnologies seller in Q4 2020 was Versant Venture Management, an estimated $24.7M sold.
Based on aggregated 13F filings for Q4 2020.